Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This webpage provides access options for JAMA Dermatology but does not contain research findings or results.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

This study developed and validated a precise and rapid HPLC method to simultaneously determine Minoxidil and Finasteride in pharmaceuticals, demonstrating successful application for routine quality control without interference from excipients.

In this study, most male patients with androgenic alopecia who transitioned from oral to topical finasteride with minoxidil maintained good hair density.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

In this study, intradermal therapy with Minoxidil, growth factors, and vitamins showed a slight advantage in increasing hair volume over a combination with Finasteride for androgenic alopecia.

This case study describes a 21-year-old man who experienced a hemorrhagic stroke potentially linked to finasteride and minoxidil use for androgenic alopecia, emphasizing the need for thorough medication history in young stroke patients.

This study found that finasteride- and minoxidil-loaded nanoparticles in a gel improved skin permeability and drug retention, suggesting a promising approach for topical alopecia treatment with reduced dosing frequency and side effects.

Method accurately measures finasteride in tablets using finasteride-BSA interaction.

Finasteride increases hair growth, prolongs hair cycle, and lowers dihydrotestosterone levels.

In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.

This study found that testosterone therapy improved physical performance and strength in older men with low testosterone over 36 months, whether administered alone or with finasteride.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study found that lowering serum DHT levels with 5 mg finasteride daily did not significantly alter serum gonadotropin levels in healthy young men after 28 days.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

This study found that 9 out of 12 women with acne or alopecia showed subjective improvement with finasteride treatment despite having normal free testosterone levels, suggesting a potential role of 5alpha-reductase activity.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

Long-term use of finasteride and minoxidil may harm male reproductive health in mice.

This study reviewed the literature on Minoxidil and finasteride for androgenetic alopecia, finding both drugs effective but noting potential side effects, with combined therapy possibly enhancing efficacy and patient adherence while reducing adverse effects.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

This study found that finasteride and minoxidil act as hormone disruptors in mice, with finasteride having a more significant association with reproductive injuries, such as damage to the epididymis and reduced semen volume.